Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB +0.25%85 EV-to-EBITDA is 6.89 as of Aug. 21, 2026, which is 6% below its 10-year median of 7.34. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT127.67 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 739 Drug Manufacturers companies, ACME Laboratories ranks better than 76.18% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ACME Laboratories's enterprise value is BDT38,327 Mil.
ACME Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was BDT5,561 Mil. Therefore, ACME Laboratories's EV-to-EBITDA for today is 6.89.
The historical rank and industry rank for ACME Laboratories's EV-to-EBITDA or its related term are showing as below:
DHA:ACMELAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.86 Med: 7.34 Max: 10.52
Current: 6.9
During the past 9 years, the highest EV-to-EBITDA of ACME Laboratories was 10.52. The lowest was 2.86. And the median was 7.34.
DHA:ACMELAB's EV-to-EBITDA is ranked better than 76.18% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.97
vs DHA:ACMELAB: 6.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ACME Laboratories's PE Ratio (TTM) for today is calculated as:
ACME Laboratories's share price for today is BDT81.10.
ACME Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT9.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ACME Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's EV-to-EBITDA falls into.
ACME Laboratories's current Enterprise Value is BDT38,327 Mil.
ACME Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT5,561 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a EV-to-EBITDA of 6.89 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ACME Laboratories. This is near median its historical median of 7.34. Over the past decade, ACME Laboratories' EV-to-EBITDA has ranged from 2.86 to 10.52. According to the industry distribution chart, ACME Laboratories ranks #176 out of 739 companies in the Drug Manufacturers industry, placing it in the top 23.8%.
Is ACME Laboratories' EV-to-EBITDA too high?
ACME Laboratories' current EV-to-EBITDA of 6.89 is near median its 10-year median of 7.34. Over the past 10 years, this metric has ranged from a low of 2.86 to a high of 10.52. The Drug Manufacturers industry median EV-to-EBITDA is 12.97. ACME Laboratories' value of 6.89 is 46.9% below this industry median. Based on the distribution chart, ACME Laboratories ranks #176 out of 739 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #176 out of 739 companies for EV-to-EBITDA. This places ACME Laboratories in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.97. ACME Laboratories' value of 6.89 is 46.9% below this benchmark. Historically, ACME Laboratories' own EV-to-EBITDA has ranged from 2.86 to 10.52 over the past decade. While the company's 10-year median is 7.34 vs. the industry median of 12.97, ACME Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.97, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current EV-to-EBITDA of 6.89 is 46.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ACME Laboratories. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current EV-to-EBITDA is 6.89, which is near median its own 10-year median of 7.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT127.67, compared to a current price of BDT81.10 — trading 36.5% below its estimated fair value. The current EV-to-EBITDA is 6.89, which is near median its 10-year median of 7.34 and 46.9% below the Drug Manufacturers industry median of 12.97. ACME Laboratories' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current EV-to-EBITDA is 6.89 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT81.10 is trading 36.5% below its estimated GF Value™ of BDT127.67.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
EV-to-EBITDA: 6.89 (near median its 10-year median of 7.34)
GF Value™: BDT127.67 vs. price of BDT81.10 (36.5% below fair value)
Industry Position: 46.9% below the Drug Manufacturers median (#176 of 739)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score
Get the complete analysis for DHA:ACMELAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
